research Demodicidose generalizada em cão da raça Teckel: Relato de caso
A young Teckel dog had severe skin issues due to mites, worsened by incorrect treatment, needing specific medications and prevention by not breeding affected dogs.
Search
for
Sort by
Research
870-900 / 1000+ results
research Alopecia na mulher
The study concluded that hair loss treatments should be tailored to the specific type of alopecia and individual patient needs.
research Sudden improvement of alopecia universalis and psoriatic arthritis while receiving upadacitinib: a case-based review
Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.
research Janus kinase inhibition in Down syndrome: 2 cases of therapeutic benefit for alopecia areata
JAK inhibitors helped treat hair loss in two people with Down syndrome.
research Treatment Challenges in Alopecia Areata: Insights From a Case of Baricitinib Therapy Failure
Baricitinib may not always prevent relapse in alopecia areata.
research “Nomen Omen: The Myth of God Janus”
The name Janus is fitting for JAK inhibitors as they revolutionize dermatology treatments.
research Baricitinib for Alopecia Universalis Following Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms
Baricitinib effectively regrew hair in a woman with alopecia universalis after other treatments failed.
research Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review
JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.
research BH14 Irish dermatologists’ experience with Janus kinase inhibitors in alopecia areata
Irish dermatologists urgently need guidelines for using JAK inhibitors in treating alopecia areata.
research BH17 Bridging the gap: identifying dual-targeting therapies for patients with alopecia areata and coexisting immune-mediated inflammatory diseases
Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.
research Reporte de caso: alopecia areata universal tratada exitosamente con baricitinib
Baricitinib successfully treated severe hair loss.
research Baricitinib in Dermatology: Expanding Therapeutic Horizons Beyond Alopecia Areata
Baricitinib shows promise for treating various skin conditions beyond alopecia areata.
research A case of atopic dermatitis with alopecia universalis in a patient treated with abrocitinib
Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.
research Ivarmacitinib in atopic dermatitis presenting with prurigo nodularis-like lesions and alopecia areata: a case report
Ivarmacitinib may effectively treat complex atopic dermatitis and related hair loss.
research Autoinmune Alopecia/Alopecia Areata
New drugs, baricitinib and ritlecitinib, are effective for severe alopecia areata.
research Janus kinase (JAK)
JAK inhibitors may help treat alopecia areata and promote hair regrowth.
research [JAK INHIBITORS FOR THE TREATMENT OF ALOPECIA AREATA].
JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.
research The development of oral hairy leukoplakia during JAK inhibitor baricitinib therapy
A man developed oral hairy leukoplakia while on baricitinib, a medication for alopecia and arthritis, and doctors should watch for such side effects.
research Upadacitinib for the Treatment of Systemic Immune Co-Morbidity in One Case: Alopecia Areata, Vitiligo, Ankylosing Spondylitis, and Allergic Rhinitis-Asthma – Multifaceted Control
Upadacitinib improved multiple immune-related conditions in one patient.
research ISIDLB1777 - A novel ex vivo model of human hair follicle immune privilege collapse reveals the potential of farudodstat, a DHODH inhibitor, as a therapeutic for alopecia areata treatment
Farudodstat may effectively treat alopecia areata by protecting hair follicles without harmful effects.
research A Review of JAK Inhibitors for Treatment of Alopecia Areata in the Military Health Care System
JAK inhibitors like baricitinib and ritlecitinib are effective new treatments for severe alopecia areata.
research Janus kinase inhibitor as a therapeutic option in alopecia areata. Case report
JAK inhibitors like tofacitinib can effectively treat severe alopecia areata.
research Upadacitinib in the treatment of a patient with the triad of atopic dermatitis, vitiligo, and alopecia areata: a case report and literature review
Upadacitinib effectively treated severe atopic dermatitis, vitiligo, and alopecia areata in one patient.
research Irish dermatologists’ experience with JAK inhibitors in alopecia areata
Irish dermatologists use JAK inhibitors for alopecia areata but want standardized treatment guidelines.
research Tombo em João Pessoa dá força a Memorial da Arquitetura Paraibana
Targeted cancer drugs can cause skin reactions, so dermatologists must manage these effects.
research Dual inhibitors of urease and carbonic anhydrase-II from Iris species
Some natural compounds from Iris plants can block enzymes related to certain disorders, with a few affecting both targeted enzymes.
research Integrated Safety Analysis of Ritlecitinib for the Treatment of Alopecia Areata (AA) From the Phase 2 and Phase 3 ALLEGRO Clinical Trial Program
Ritlecitinib is safe for treating alopecia areata for up to 48 weeks.
research Alopecia Areata: Case report and review of pathophysiology and treatment with Jak inhibitors
JAK inhibitors like tofacitinib may effectively treat Alopecia Areata.
research Successful Treatment of Extensive Ritlecitinib-Refractory Alopecia Areata with Upadacitinib
Upadacitinib effectively treated alopecia areata when other treatments failed.
research Alopecia Areata – Effects of Treatment with Upadacitinib – Two Case Reports
Upadacitinib can effectively regrow hair in alopecia areata patients without worsening sarcoidosis.